Literature DB >> 6208336

Serotonin receptor changes in dementia of the Alzheimer type.

A J Cross, T J Crow, I N Ferrier, J A Johnson, S R Bloom, J A Corsellis.   

Abstract

Serotonin receptors were assessed in post-mortem brains of control and Alzheimer-type dementia (ATD) patients using ligand binding techniques. Differential losses of serotonin S1 and S2 receptors were present in neocortex, hippocampus, and amygdala of ATD patients, whereas no significant changes were observed in basal forebrain and basal ganglia. Losses of S1 receptors were significantly age-related in the ATD group, suggesting they occurred at a later stage of the disease process. Losses of S2 receptors were considerably greater (with a reduction to 35% of control in temporal cortex) and were not age-related in ATD. Significant correlations were observed within the ATD group between S2 receptor binding and somatostatin immunoreactivity in temporal and frontal cortices. Thus the loss of S2 receptors in ATD may be a relatively early change in the disease process, and may precede the changes in ascending serotonergic neurones.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208336     DOI: 10.1111/j.1471-4159.1984.tb06081.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

Authors:  A W Procter; P T Francis; G C Stratmann; D M Bowen
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

2.  An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Masanori Ishikawa; Hiroyasu Akatsu; Eric E Abrahamson; Milos D Ikonomovic; Takashi Asada
Journal:  Neuropathology       Date:  2011-01-27       Impact factor: 1.906

3.  Herpes simplex virus: a role in the aetiology of Alzheimer's disease?

Authors:  G W Roberts; G R Taylor; G I Carter; J A Johnson; C Bloxham; R Brown; T J Crow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-02       Impact factor: 10.154

4.  Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.

Authors:  Mitchell K P Lai; Shirley W Tsang; Margaret M Esiri; Paul T Francis; Peter T-H Wong; Christopher P Chen
Journal:  Psychopharmacology (Berl)       Date:  2010-07-13       Impact factor: 4.530

5.  [3H]ketanserin binding in human brain postmortem.

Authors:  D Marazziti; A Rossi; L Palego; G Giannaccini; A Naccarato; A Lucacchini; G B Cassano
Journal:  Neurochem Res       Date:  1997-06       Impact factor: 3.996

6.  Disturbed neurotransmitter transporter expression in Alzheimer's disease brain.

Authors:  Kevin H Chen; Edmund A Reese; Hyung-Wook Kim; Stanley I Rapoport; Jagadeesh S Rao
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  Human serum Cohn fraction IV (alpha-globulin [correction of globin] enriched) inhibits ligand binding at neurotransmitter receptors in human brain.

Authors:  A C Andorn; M A Pappolla; H Fox; F K Klemens; P A Martello
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.

Authors:  B Lemmer; L Langer; T Ohm; J Bohl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

9.  Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.

Authors:  J T Little; A Broocks; A Martin; J L Hill; L E Tune; C Mack; M Cantillon; S Molchan; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

10.  Increased in vitro phosphorylation of a Mr 60,000 protein in brain from patients with Alzheimer disease.

Authors:  T Saitoh; K R Dobkins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.